AbbVie Inc. (ETR: 4AB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 294.59B |
| Revenue (ttm) | 49.79B |
| Net Income (ttm) | 4.56B |
| Shares Out | n/a |
| EPS (ttm) | 2.57 |
| PE Ratio | 64.67 |
| Forward PE | n/a |
| Dividend | 5.88 (3.51%) |
| Ex-Dividend Date | Jan 15, 2025 |
| Volume | 55 |
| Average Volume | 1,453 |
| Open | 167.56 |
| Previous Close | 167.84 |
| Day's Range | 165.52 - 168.36 |
| 52-Week Range | 141.98 - 192.50 |
| Beta | 0.61 |
| RSI | 44.03 |
| Earnings Date | Jan 31, 2025 |
About AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.
Financial numbers in USD Financial StatementsNews
Income & Growth: 3 Of The Best Dividend Stocks For Any Market
Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy. Read more about our stock picks on Seeking Alpha.
Humira Holds Firm at 72% Market Share--AbbVie Fends Off Biosimilar Surge
Humira Holds Firm at 72% Market Share--AbbVie Fends Off Biosimilar Surge
AbbVie retains Humira market share above 70%: report
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
AbbVie may commit less capital to psych drugs: report
AbbVie Inc. (ABBV) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
AbbVie Inc. (ABBV) JPMorgan 43rd Annual Healthcare Conference (Transcript)
Call Start: 11:15 January 1, 0000 11:56 AM ETAbbVie Inc.
AbbVie to 'commit less capital' towards psychiatric drugs, CEO says
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday.
My Dividend Stock Portfolio: $10,000 In Dividends In 2024 - 97 Holdings With 13 Buys
In December, I invested around $1,200 primarily in Business Development Companies, boosting my annual dividend income by $131 with a full-year total of almost $1,700.
Alzamend Neuro to Present at the Sequire Investor Summit
ATLANTA--(BUSINESS WIRE)---- $ABBV #ALZN--Alzamend Neuro to Present at Sequire Investor Summit; Company to Report Progress with Clinical Trials to be Initiated in 2025 and Expected Milestones.
AbbVie goes ex dividend tomorrow
AbbVie Inc: An Exploration into Its Intrinsic Value
AbbVie Inc: An Exploration into Its Intrinsic Value
AbbVie Has Immense Cash Flow Potential
AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations. Read more about ABBV stock here.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Drugmakers rush to sign deals on first day of industry conference
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
AbbVie, AbCellera expand collaboration into T-cell engagers
AbbVie (ABBV) and AbCellera (ABCL) have expanded their collaboration to include the discovery of T-cell engagers for the treatment of cancer.
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Johnson & Johnson's $14.6 billion acquisition ... Full story available on Benzinga.com
China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer drug candidate outside China.
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) i...
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI and NORTH CHICAGO, Ill. , Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option t...
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
NORTH CHICAGO, Ill. and SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to li...
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
NORTH CHICAGO, Ill. and SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to lic...
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO wil...
11 Upcoming Dividend Increases, Including A Dividend King
Hormel Foods extends its 52-year dividend streak with a 2.6% increase; the group averages a 5.9% increase, median 5.8%. My strategy focuses on buying, holding, and adding to companies with consistent ...
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
AbbVie (ABBV) shares fell Friday after the biotech firm announced it would take an estimated $3.5 billion impairment charge because of the failure of one of its drugs.